Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $79.82.

A number of equities research analysts recently weighed in on IMCR shares. Morgan Stanley decreased their target price on Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Guggenheim cut Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a research report on Monday, September 9th. Barclays lowered their price target on shares of Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a report on Friday, August 9th. Finally, Needham & Company LLC reduced their price objective on shares of Immunocore from $81.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, September 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IMCR. Exchange Traded Concepts LLC raised its position in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock valued at $158,000 after purchasing an additional 1,461 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Immunocore in the first quarter valued at about $423,000. Nan Fung Group Holdings Ltd acquired a new position in Immunocore during the 1st quarter worth about $439,000. Connective Portfolio Management LLC bought a new stake in Immunocore during the 3rd quarter worth about $218,000. Finally, DNB Asset Management AS increased its position in Immunocore by 35.0% in the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company's stock valued at $244,000 after acquiring an additional 1,868 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Price Performance

Shares of IMCR stock remained flat at $33.31 during trading hours on Tuesday. The stock had a trading volume of 173,399 shares, compared to its average volume of 545,112. Immunocore has a one year low of $29.72 and a one year high of $76.98. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.67 billion, a PE ratio of -27.30 and a beta of 0.72. The business's fifty day simple moving average is $33.67 and its two-hundred day simple moving average is $41.68.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. During the same period in the prior year, the firm earned ($0.37) EPS. The business's revenue was up 26.2% on a year-over-year basis. As a group, research analysts expect that Immunocore will post -1.67 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.